ANTIBODY FORMULATION AND THERAPEUTIC REGIMENS

There is disclosed a pharmaceutical formulation comprising an aqueous solution of a glutamic acid buffer and an antibody comprising a heavy chain CDR1 comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO: 11, wherein said antibody, or fragment thereof, specifically binds human IL-17 receptor A, and wherein: a) said glutamic acid buffer comprises a glutamic acid con centration of 5-30 mM ? 0.2 mM; b) said glutamic acid buffer comprises a pH of 4.5-5.2 ? 0.2; c) said formulation further comprises 2-4% praline (w/v) and 0.005-0.02% (w/v) polysorbate 20; and d) said antibody is at a concentration of 100 to 180 mg/ml.